Growth Hormone in EB
May 24, 2022 updated by: Hagar El Sayed, Cairo University
Assessment of Growth Hormone and Insulin-like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophia
Growth is extremely affected in epidermolysis bullosa patients
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Studying the role of growth hormone and ILGF-1 in EB may pave the to new therapeutic modality that could improve the growth in those children and avoid the irreversible sequelae that affected subjects experience after adulthood
Study Type
Observational
Enrollment (Anticipated)
50
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 12 years (Child)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Children with EB dystrophica
Description
Inclusion Criteria:
- Children with EB dystrophica
Exclusion Criteria:
- Adults with the same disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
level of growth hormone and insulin like growth factor 1
Time Frame: 2 weeks
|
laboratory test
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 25, 2022
Primary Completion (Anticipated)
June 10, 2022
Study Completion (Anticipated)
June 15, 2022
Study Registration Dates
First Submitted
May 20, 2022
First Submitted That Met QC Criteria
May 24, 2022
First Posted (Actual)
May 25, 2022
Study Record Updates
Last Update Posted (Actual)
May 25, 2022
Last Update Submitted That Met QC Criteria
May 24, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vesiculobullous
- Skin Abnormalities
- Collagen Diseases
- Epidermolysis Bullosa
- Epidermolysis Bullosa Dystrophica
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones
- Mitogens
Other Study ID Numbers
- Growth in EB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.